GlassScriptPhysician profile
Kayla Craig
NPI 1457977274
$397.92
in general payments reported to CMS, 2019-2025
10 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $257 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $397.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $98.24 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Axsome Therapeutics, INC. | $87.90 | 2024 | Auvelity |
| Lilly USA, LLC | $62.64 | 2024-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $40.49 | 2025 | Ozempic, Wegovy |
| Xeris Pharmaceuticals, INC. | $20.11 | 2025 | Keveyis |
| Hologic Sales and Service, LLC | $19.98 | 2024 | Third Wave, Aptima, Thinprep 2000 Processor |
| Amgen INC. | $19.05 | 2025 | Repatha, Otezla |
| Azurity Pharmaceuticals, INC. | $17.86 | 2025 | |
| Glaxosmithkline, LLC. | $17.20 | 2024 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $14.45 | 2024 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Craig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.